Last updated: February 5, 2024
Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Overall Status: Active - Recruiting
Phase
3
Condition
Bone Metastases
Osteosarcoma
Bone Neoplasm
Treatment
18F-sodium fluoride
Clinical Study ID
NCT04842071
CIMS-2008-01
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated;
- Pediatric patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated foroncologic or infectious reasons
- Able to tolerate supine position
- Written consent
Exclusion
Exclusion Criteria:
- Healthy subjects
- Pregnancy
- Unable of maintaining supine position for more than 15 minutes
- Refusal to sign the consent form
- Known allergy or hypersensitivity to 18F-NaF or any of its constituants.
Study Design
Total Participants: 2500
Treatment Group(s): 1
Primary Treatment: 18F-sodium fluoride
Phase: 3
Study Start date:
January 01, 2008
Estimated Completion Date:
December 31, 2025
Connect with a study center
CHUS
Sherbrooke, Quebec J1H 5N4
CanadaActive - Recruiting
Université deSherbrooke
Sherbrooke, Quebec J1H5N4
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.